Abivax

Address
7 Boulevard Haussmann

Sponsor Overview

assignment
11
sponsored trials
science
1
molecule
location_city
254
research centres
public
19
countries
person_search
269
investigators

Specializations

Inflammatory Bowel Disease Research

The sponsor demonstrates a concentrated focus on inflammatory bowel diseases, particularly ulcerative colitis. Research efforts encompass both moderate to severe ulcerative colitis and investigations into maintenance therapy for patients who have achieved clinical remission. The programme extends to understanding disease activity assessment and long-term management strategies for chronic intestinal inflammation.

  • Ulcerative Colitis Treatment
  • Maintenance of Remission
  • Chronic Inflammatory Conditions

The research portfolio includes extensive evaluation of therapeutic interventions across diverse patient populations, with particular attention to those experiencing persistent disease activity despite conventional treatment approaches.

Rheumatological and Autoimmune Disorders

Significant research investment is directed toward rheumatoid arthritis, specifically targeting patients with active rheumatoid arthritis who have demonstrated inadequate response to existing therapies. The sponsor explores novel therapeutic pathways for managing chronic autoimmune arthritis and addressing persistent joint inflammation. Research encompasses both systemic autoimmune conditions and their impact on musculoskeletal function.

  • Rheumatoid Arthritis
  • Autoimmune Joint Disease
  • Chronic Inflammatory Arthritis

The therapeutic development programme emphasizes addressing unmet medical needs in patients who continue to experience disease activity despite treatment with conventional disease-modifying therapies.

Dermatological Inflammatory Conditions

The sponsor maintains an active research programme in atopic dermatitis, focusing on patients with moderate to severe atopic dermatitis. Investigations explore therapeutic options for individuals experiencing inadequate disease control and chronic skin inflammation. The research extends to understanding immune-mediated skin disorders and their systemic manifestations.

  • Atopic Dermatitis
  • Chronic Inflammatory Skin Disease
  • Immune-Mediated Dermatological Conditions

The dermatological research portfolio addresses the complex interplay between cutaneous inflammation and systemic immune dysregulation in chronic skin conditions.

Infectious Disease and Viral Immunology

Research activities encompass human immunodeficiency virus infection, with particular emphasis on HIV-1 infection management. The sponsor investigates therapeutic strategies for chronic viral infections and explores approaches to modulating immune responses in the context of persistent viral disease. Studies include evaluation of interventions in patients with suppressed viral load receiving antiretroviral therapy.

  • HIV Infection
  • Viral Immunology
  • Chronic Infectious Disease Management

The infectious disease programme addresses both viral suppression and immune reconstitution in patients with chronic viral infections under therapeutic management.

Immunological Mechanisms and Drug Safety

The sponsor conducts comprehensive investigations into pharmacokinetics, pharmacodynamics, and drug-drug interactions across various therapeutic contexts. Research includes evaluation of bioavailability, assessment of therapeutic interventions in healthy volunteers, and exploration of immune system modulation. Studies address potential interactions with common medications including oral contraceptives and evaluate safety profiles across diverse patient populations.

  • Pharmacological Interactions
  • Immune System Modulation
  • Clinical Pharmacology

The research framework encompasses fundamental understanding of drug behavior, immune response mechanisms, and safety considerations essential for therapeutic development across multiple disease states.

Sponsored Trials

Trial Name Country Status
A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitisBelgium BelgiumFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainNot Yet Recruiting
A randomized, double-blind, placebo-controlled, multicenter phase III study to evaluate the efficacy and safety of ABX464 once daily for induction treatment in subjects with moderately to severely active ulcerative colitisBelgium BelgiumBulgaria BulgariaCroatia CroatiaCzechia CzechiaFrance FranceGermany GermanyHungary HungaryIreland IrelandItaly ItalyLithuania LithuaniaPoland PolandRomania RomaniaSlovakia SlovakiaSpain SpainNot Recruiting
A Study to Test How Well Obefazimod Works and How Safe It Is for Patients with Moderately to Severely Active Ulcerative ColitisBelgium BelgiumFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainNot Yet Recruiting
Efficacy and Safety of Obefazimod (ABX464) in Adults with Moderately to Severely Active Ulcerative Colitis: A Randomized Placebo‑Controlled Phase III StudyBelgium BelgiumFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainNot Yet Recruiting
Efficacy and Safety of Obefazimod for Induction in Adults with Moderately to Severely Active Ulcerative Colitis: Randomized, Double‑Blind, Placebo‑Controlled III TrialAustria AustriaBelgium BelgiumBulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsNot Recruiting
Evaluation of Obefazimod Efficacy and Safety in Patients with Moderately to Severely Active Crohn's Disease: A Phase 2b Multicenter, Double-Blind, Placebo-Controlled StudyBelgium BelgiumCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandRomania RomaniaSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsRecruiting
Evaluation of Pharmacokinetics, Safety, and Tolerability of Obefazimod in Patients with Renal Impairment and Normal Renal Function with Ulcerative ColitisGermany GermanyNot Recruiting
Evaluation of the Pharmacokinetic Interaction Between Obefazimod and Ethinyl Estradiol/Drospirenone in Healthy Female Subjects of Childbearing PotentialBelgium BelgiumNot Recruiting
Investigation of Obefazimod and Rosuvastatin Pharmacokinetics in Healthy Male Subjects with Moderately to Severely Active Ulcerative ColitisFrance FranceNot Recruiting
Long-term Safety and Efficacy Evaluation of Obefazimod (ABX464) in Moderate to Severe Ulcerative Colitis: A Phase II Open-label StudyAustria AustriaBelgium BelgiumCzechia CzechiaFrance FranceGermany GermanyHungary HungaryItaly ItalyPoland PolandSlovakia SlovakiaSlovenia SloveniaSpain SpainNot Recruiting
1–10 of 11
1 / 2

Data & Insights

science
Molecule Portfolio
Compounds under investigation
1
Exclusive Molecules
out of 1 total (100% not shared with other sponsors)

This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
52%
Return partnership rate
133 of 254 sites collaborated multiple times

This sponsor has worked with 254 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Digestive System Diseases9 trials
    280 other sponsors
  • 2.
    Immune System Diseases2 trials
    322 other sponsors

Partnered Research Centres

254 centres
location_city
assignment1
"DCC Sveti Pantaleymon" OOD
Address
24 Trite bora Str.,, Pleven
Learn morearrow_forward
location_city
assignment32
1 Wojskowy Szpital Kliniczny Z Poliklinika samodzielny publiczny zakład opieki zdrowotnej W Lublinie
Address
Ul. Aleje Raclawickie 23, 20-049 Lublin
Learn morearrow_forward
location_city
assignment11
Accout Center s.r.o.
Address
Hviezdoslavova 402/19, 936 01 Šahy
Learn morearrow_forward
location_city
assignment95
Acibadem City Clinic Diagnostic And Consultation Center Tokuda EAD
Address
Bulevard Nikola Yonkov Vaptsarov 51b, 1407 Sofia
Learn morearrow_forward
location_city
assignment9
Advanced Technology Corporation
Address
Avenue Hippocrate 15, 4000 Liège
Learn morearrow_forward
location_city
assignment283
Algemeen Ziekenhuis Delta
Address
Deltalaan 1, 8800 Roeselare
Learn morearrow_forward
Page 1 of 43

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Abivax.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.